Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I like how they do it .On every sale they drop 1p ,on the buys price does't go up 1p...lol
Yes, tiny share cap, but comparatively large debt, all dependent on positive drug trials. And there are many cos in this field incuding the biggest pharmas in the world. So I shall add to my Flutter Fund watch List for now.
Thanks ,,Interesting and with only 36 million shares ?....
Yes I read about Jim Mellon, what position has he got here ???
At least they show the sells ..not the buys ...
Is there any news soon here.............
Note but do they mean anything?
DNL - anyone? RNS's out. f
North.... house broker, ho well.....
Thanks - I see it now - from Northland.
Great update. All progressing well.
Looks like I am right so in for a long long wait still before any news on INT230-6 etc Original plan stated 07/2018 https://clinicaltrials.gov/archive/NCT03058289/2017_02_19 Latest version shows 07/2019 https://www.clinicaltrials.gov/ct2/show/NCT03058289?term=03058289&rank=1
Been a while since I checked in here so from my reading am I correct in thinking that the estimate for first results has now been pushed back to July 2019 instead of July 2018 as previously planned?
http://www.courant.com/business/hc-biz-westport-cancer-therapy-20171222-story.html
Was under the impression that we were fully funded until the middle of next year at the very earliest. This share does that sometimes, it seems to move for no reason up or down.
I cant see any reason for the drop unless people have got impatient.... im also woundering if there could be a placing of shares on the way????
Disappointing to see the sp drop so much in recent days. There does not appear to be any fundamental reason for it. Maybe investors are freeing up cash for more near-term opportunities. Who knows. Still a long term fantastic buy in my opinion, and now even cheaper to buy. Anyone else out there.......? This feels like the Marie Celeste at times!
The following has been copied and pasted from the RNS of FFWD, which also has a stake in Intensity. Very encouraging news. In Q3 2017 one new patient participated in Intensity's on-going trial. There have been no dose limiting side effects to date. Preliminary indication is that the patient's injected tumor shrank. Intensity has reported to shareholders that this preliminary tumor regression finding is encouraging. The regulatory agencies mandated treatment at a low drug dose, low concentration (within the tumor) and minimal dosing frequency.
No clinical trial results until next year but there may well be updates on how the trial is progressing.
What news are you expecting they have already said no test news till middle of next year?
Good to see SALV adding to its portfolio of investments. Hopefully news on Intensity soon.
Hi, yes I'm watching this one too. Potential for huge upside over the next couple of years but you just have to be patient. The management are the best in their field in cancer immunotherapy. Clinical trials and proof of concept take time and for commercial sensitivity reasons the company cannot report on clinical trial progress, but there is plenty going on for sure.
????